← Back to Screener
Jaguar Health, Inc. (JAGX)
Price$2.80
Value ScoreA
Growth ScoreB
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-102.00%
Price vs S&P 500 (4W)-6.66%
VGM Score57.88
Market Capitalization$1.69M
All Metrics
Book Value / Share (Quarterly)$53.42
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-1.26%
Cash Flow / Share (Quarterly)$-20.38
Price vs S&P 500 (YTD)-99.57%
Gross Margin (TTM)85.06%
Net Profit Margin (TTM)-115.39%
EPS (TTM)$-713.94
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$-713.94
Revenue Growth (5Y)4.17%
EPS (Annual)$-801.83
ROI (Annual)-84.95%
Gross Margin (Annual)67.21%
Net Profit Margin (5Y Avg)-565.36%
Cash / Share (Quarterly)$19.57
Revenue Growth QoQ (YoY)815.63%
ROA (Last FY)-139.43%
Revenue Growth TTM (YoY)155.96%
EBITD / Share (TTM)$-145.11
ROE (5Y Avg)-412.67%
Operating Margin (TTM)-97.17%
Cash Flow / Share (Annual)$-119.03
P/B Ratio0.30x
P/B Ratio (Quarterly)1.46x
Net Income / Employee (Annual)$-1,136,900
EV / Revenue (TTM)0.93x
Net Interest Coverage (TTM)-7.53x
ROA (TTM)-78.67%
EPS Incl Extra (Annual)$-801.83
Current Ratio (Annual)0.50x
Quick Ratio (Quarterly)0.25x
3-Month Avg Trading Volume0.05M
52-Week Price Return-97.95%
Revenue / Employee (TTM)$629,100
Tangible BV / Share (Quarterly)$3.89
P/S Ratio (Annual)0.15x
Asset Turnover (Annual)0.30x
52-Week High$144.55
Operating Margin (5Y Avg)-448.71%
EPS Excl Extra (Annual)$-801.83
CapEx CAGR (5Y)42.41%
26-Week Price Return-94.07%
Quick Ratio (Annual)0.23x
13-Week Price Return-86.72%
Total Debt / Equity (Annual)3.64x
Current Ratio (Quarterly)0.50x
Enterprise Value$27.56M
Revenue / Share Growth (5Y)-43.97%
Asset Turnover (TTM)0.68x
Book Value / Share Growth (5Y)751.93%
Revenue / Employee (Annual)$244,900
Inventory Turnover (Annual)0.40x
Pretax Margin (Annual)-469.09%
Cash / Share (Annual)$4.86
3-Month Return Std Dev158.97%
Gross Margin (5Y Avg)71.78%
Net Income / Employee (TTM)$-726,000
ROE (Last FY)-393.98%
Net Interest Coverage (Annual)-4.70x
EPS Basic Excl Extra (Annual)$-801.83
Receivables Turnover (TTM)45.81x
Total Debt / Equity (Quarterly)5.47x
EPS Incl Extra (TTM)$-713.94
Receivables Turnover (Annual)7.55x
ROI (TTM)-100.53%
P/S Ratio (TTM)0.06x
Pretax Margin (5Y Avg)-570.46%
Revenue / Share (Annual)$172.73
Tangible BV / Share (Annual)$-5.37
Price vs S&P 500 (52W)-122.31%
Year-to-Date Return-91.41%
5-Day Price Return-14.37%
EPS Normalized (Annual)$-801.83
ROA (5Y Avg)-98.32%
Net Profit Margin (Annual)-464.20%
Month-to-Date Return-21.13%
Cash Flow / Share (TTM)$-3.41
EBITD / Share (Annual)$-687.18
Operating Margin (Annual)-414.45%
LT Debt / Equity (Annual)2.41x
ROI (5Y Avg)-111.61%
LT Debt / Equity (Quarterly)1.36x
EPS Basic Excl Extra (TTM)$-713.94
P/TBV (Quarterly)26.17x
P/B Ratio (Annual)1.22x
Inventory Turnover (TTM)0.48x
Pretax Margin (TTM)-117.28%
Book Value / Share (Annual)$16016.48
Price vs S&P 500 (13W)-94.97%
Beta-0.09x
Revenue / Share (TTM)$57.33
ROE (TTM)-582.86%
52-Week Low$2.53
vGradeA
gGradeB
mGradeF
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-13.60est. -2.08
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
JAGXJaguar Health, Inc. | A | B | F | $2.80 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Jaguar Health is a commercial-stage biopharmaceutical company developing plant-based, non-opioid prescription medicines for gastrointestinal disorders, primarily chronic diarrhea. Its lead product, Mytesi, is a first-in-class anti-secretory agent with potential applications across multiple GI indications in both human and animal health markets. The company generates revenue primarily from its human health segment.